CALL US AT 800-952-0521

FDA OKs Xeomin® for frown lines

Tuesday, August 02, 2011

Washington — The Food and Drug Administration (FDA) has approved Xeomin® (incobotulinumtoxinA, Merz Aesthetics) for temporary improvement of moderate to severe glabellar lines, Medscape Today reports.

According to a Merz statement, the approval is based on the results of two multicenter U.S. clinical trials involving 547 healthy adults. In both studies, Xeomin® injections significantly improved the appearance of glabellar lines in 30 days when compared with placebo. Headache was the most common adverse reaction observed.

Under the brand name Bocouture, Xeomin® is already approved in 14 European countries including Germany, the United Kingdom, France, Italy and Spain. It was FDA-approved in 2010 for the treatment of cervical dystonia and blepharospasm.


Blog Categories

Related Posts

Botulinum Toxin Options

By Sydney Gatta, RN We’ve all heard of Botox, right?! While Botox has been around for a very long time, it has become wildly more